{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.176","meta":{"versionId":"6","lastUpdated":"2021-03-19T01:00:22.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.176","version":"20210319","name":"Immunotherapy Administration","status":"active","date":"2021-03-19T01:00:22-04:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","concept":[{"code":"XW03351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW033C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW04351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW043C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW23346","display":"Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6"},{"code":"XW23376","display":"Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6"},{"code":"XW24346","display":"Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6"},{"code":"XW24376","display":"Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6"}]}]},"expansion":{"identifier":"urn:uuid:b46db3ad-d635-4e21-99ff-0a008d4ca83d","timestamp":"2022-06-10T08:41:13-04:00","total":0,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}]}}